Debate heats up over Librela safety profile

Discussion in the veterinary community about the safety profile of a popular new osteoarthritis drug for dogs is continuing with vigor, stoked by three research papers — two backed by the drug's manufacturer, Zoetis — that give contrasting impressions of the risk of side effects.

Zoetis maintains that the vast majority of patients receiving the injectable treatment, branded Librela, have positive experiences and that associated adverse events are rare.

This story was published on July 17, 2025.